Progress in the Application of Lipoarabinomannan Detection Kit (Chemiluminescence Method) in the Early Diagnosis of Tuberculosis

Biological Basis of LAM Detection and Advantages of Chemiluminescence Technology

Lipoarabinomannan (LAM) is a lipopolysaccharide component of the mycobacterial cell wall that can be released into the bloodstream during active infection with Mycobacterium tuberculosis and appears in urine after renal filtration. Urine specimen collection is non-invasive and carries low biosafety risk, making LAM detection an important supplement to conventional sputum smear microscopy or molecular testing. Chemiluminescence immunoassay (CLIA), as a highly sensitive immunoassay method, works by labeling LAM-specific antibodies with chemiluminescent substrates; upon binding to LAM in urine or serum, a luminescent reaction is catalyzed, and signal intensity is proportional to target concentration. This method typically employs a double-antibody sandwich format combined with magnetic particle separation technology, enabling completion of testing within a short time, and features a high degree of automation and good reproducibility. Compared with enzyme-linked immunosorbent assay, chemiluminescence immunoassay offers certain improvements in linear range and sensitivity, facilitating the detection of low-concentration LAM.

Clinical Application Scenarios: Focus on Special Populations and Extrapulmonary Tuberculosis

In patients co-infected with HIV and tuberculosis, low CD4+ T cell counts lead to weakened immune responses, and the sputum smear positivity rate is often less than 30%. However, urine LAM detection, being unaffected by immune status, has been confirmed by multiple studies to improve the detection rate in this patient population. Furthermore, for extrapulmonary tuberculosis (such as lymph node tuberculosis and bone tuberculosis), where conventional respiratory specimen acquisition is difficult, urine or body fluid LAM detection provides a possible auxiliary diagnostic approach. It should be noted that LAM detection results should be interpreted comprehensively in conjunction with clinical symptoms, imaging, and other laboratory tests, and should not be used alone as a basis for confirmation or exclusion. Kit products are generally recommended for preliminary screening or supplementary testing of patients with suspected tuberculosis, and clinical application requires attention to negative predictive value and further confirmation of positive results.

Common Considerations and Quality Requirements for Detection Performance

Commercially available LAM detection kits (chemiluminescence method) typically have clearly defined cut-off values determined based on clinical evaluation. During operation, specimen collection, transport, and storage conditions (e.g., urine samples should avoid repeated freeze-thaw cycles) directly affect the reliability of results. Internal controls and quality control materials for the kit should be set up according to the instructions, and calibrators should be traceable to the manufacturer's internal reference standards. In terms of equipment configuration, the chemiluminescence immunoassay analyzer should undergo regular maintenance and calibration to ensure the stability of sample loading, incubation, washing, and reading modules. Inter-assay and intra-assay variation of the kit should generally be controlled within specified allowable ranges. Given the diversity of tuberculosis strains across different regions, the antibody targets selected for the reagent should cover common genotypes to avoid missed detection due to antigenic variation.

Future Directions and Recommendations for Industry Standards

As chemiluminescence technology platforms continue to mature, LAM detection kits are expected to be optimized toward full automation and high throughput, while simultaneously exploring applicability to more body fluid matrices (such as cerebrospinal fluid and pleural/ascitic fluid). At the regulatory approval level, requirements of relevant regulations for in vitro diagnostic reagents must be followed, providing sufficient preclinical research and evaluation data from at least two clinical institutions. The industry calls for the establishment of unified LAM detection reference standards and methodological comparison systems to promote comparability of results among different kits. Overall, as a component of the tuberculosis diagnostic toolkit, this technology still requires more real-world data to support optimization of its clinical pathway.